AstraZeneca heartened by US FDA nod to antiplatelet medicine Brilinta
This article was originally published in Scrip
Executive Summary
AstraZeneca finally pulled off a US win for Brilinta (ticagrelor), with the FDA granting the OK on 20 July for the London drug maker to market the oral antiplatelet medicine as a therapy to reduce the rate of heart attack and cardiovascular death in adults with acute coronary syndrome (ACS) – an umbrella term for conditions that result from a reduction in blood flow to the heart muscle.
You may also be interested in...
Novo Readies For Victoza CV Benefit Claim With US FDA Panel Nod
HeartofType2 unbranded campaign is aimed at increasing awareness of CV disease in type 2 diabetics. FDA advisory committee strongly endorses new claim for the GLP-1 agonist but recommends limiting it to diabetics with established CV or chronic kidney disease.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.